Neogenomics shares fall 1.25% premarket after court rules in favor of patent invalidity.

Neogenomics, Inc. fell 1.25% in premarket trading, following a court ruling in favor of the company in a patent infringement case against Natera. The District Court for the Middle District of North Carolina granted NeoGenomics' motion for summary judgment, invalidating all of Natera's asserted patent claims. This ruling allows NeoGenomics to continue commercializing its RaDaR(R) ST assay, which has been launched to biopharma customers and submitted to the Centers for Medicare & Medicaid Services for approval.